PVLA at a glance
PALVELLA THERAPEUTICS, INC. (PVLA, SEC CIK 1583648) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2023 (FY2023), PALVELLA THERAPEUTICS, INC. (PVLA) reported revenue of $42.8 million and a net loss of $24.5 million. Diluted EPS was $2.17.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding PALVELLA THERAPEUTICS, INC. (PVLA) shares worth $529.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Martini Jeffrey S on November 11, 2026 of 600 shares at $168.73 per share.
- In the last 90 days, PVLA insiders reported 0 open-market purchases ($0) and 46 open-market sales ($11.1M) on Form 4, a net sale of $11.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2023
- $42.8M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 46 sells
- Net −$11.1M
- 13F holders
- 26 funds
- $529.6M · −1 vs prior quarter
- Latest 8-K
- Nov 19, 2026
- Item 7.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- No product revenue, consistent with no commercial revenue or operating cash flows expected near-term
- Net loss $24.6M vs $11.3M YoY, operating loss $22.7M vs $10.2M
- R&D expense $10.8M vs $6.5M YoY, G&A expense $11.9M vs $3.6M
- Cash and short-term investments $236.7M, operating cash outflow $38.1M, financing inflow $216.5M
- FDA Priority Review, PDUFA date February 28, 2027, planned U.S. launch first half of 2027 if approved
Risk Factors
- No material changes reported from the 2025 Form 10-K
- Financing risk: securities investment involves a high degree of risk
- Disclosure risk: quarterly results require review alongside MD&A and unaudited financial statements
- Carried-forward risks: 2025 Form 10-K risk factors remain applicable
AI summary of the PVLA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- New QTORIN™ program announced as the third product candidate from Palvella’s platform
- Investor conference call scheduled November 19, 2026 at 8:30 a.m. Eastern Time
Item 8.01: Other Events
- Third QTORIN™ product candidate announced for Extramammary Paget’s disease
- Expands PVLA’s pipeline into a rare dermatologic cancer indication
Item EX-99.1: Item EX-99.1
- Corporate presentation positions QTORIN™ docetaxel as a potential first FDA-approved EMPD therapy for an estimated >10k U.S. patients
- Human docetaxel evidence: 51.6% ORR in 93 patients, but 24.7% discontinued for adverse events and 52.7% experienced ≥Grade 3 neutropenia
Item EX-99.2: Item EX-99.2
- New QTORIN™ docetaxel program targeting EMPD, a serious rare cancer affecting more than 10,000 U.S. patients
- Potential first FDA-approved EMPD therapy, addressing repeated disfiguring surgeries and high recurrence rates
Item 2.02: Results of Operations and Financial Condition
- Fiscal-quarter results announced for period ended September 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Earnings call scheduled for November 5, 2026, covering the company’s fiscal 2026 results
- Investor presentation furnished as Exhibit 99.2, likely providing supplemental operating and financial commentary
Item EX-99.1: Item EX-99.1
- FDA accepted QTORIN rapamycin’s NDA for microcystic lymphatic malformations, with Priority Review and February 28, 2027 PDUFA target
- Potential first FDA-approved therapy for a disease affecting more than 30,000 diagnosed U.S. children and adults
Item EX-99.2: Item EX-99.2
- QTORIN rapamycin NDA accepted with Priority Review, with FDA action targeted for February 28, 2027
- Potential standalone U.S. launch in 1H 2027 for microcystic lymphatic malformations, an estimated >30,000 diagnosed patients
Item 8.01: Other Events
- FDA filing acceptance for QTORIN 3.9% rapamycin gel, advancing the treatment toward potential U.S. approval
- Priority Review signals FDA consideration of an accelerated review timeline
Item EX-99.1: Item EX-99.1
- FDA accepted QTORIN rapamycin’s NDA and granted Priority Review, establishing a February 28, 2027 PDUFA target date
- Potential first FDA-approved therapy for microcystic lymphatic malformations, addressing more than 30,000 diagnosed U.S. patients
AI summaries of PVLA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PVLA
Don't miss the next PVLA filing
- Alerts as it files. A push when PVLA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PVLA, by share count.
- Ask anything. An AI agent that reads every PVLA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Martini Jeffrey S | Sell | Nov 11, 2026 | 600 | $168.73 |
| Martini Jeffrey S | Sell | Nov 11, 2026 | 1,133 | $166.76 |
| Martini Jeffrey S | Sell | Nov 11, 2026 | 1,467 | $165.78 |
| Martini Jeffrey S | Sell | Nov 11, 2026 | 1,200 | $167.75 |
| Martini Jeffrey S | Sell | Nov 11, 2026 | 200 | $169.78 |
| Martini Jeffrey S | M | Nov 11, 2026 | 6,250 | - |
| Martini Jeffrey S | M | Nov 11, 2026 | 6,250 | $9.79 |
| Martini Jeffrey S | Sell | Nov 11, 2026 | 1,650 | $164.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $42.8M | - | - |
| Operating Income | -$29.8M | -$14.1M | -$38.6M |
| Net Income | -$24.5M | -$17.4M | -$41.7M |
| Op. Margin | -69.5% | - | - |
| Net Margin | -57.3% | - | - |
| Balance Sheet | |||
| Total Assets | $38.7M | $88.2M | $59.6M |
| Equity | $26.8M | $62.6M | $28.0M |
| ROE | -91.7% | -27.8% | -149.1% |
| Per Share | |||
| EPS | $2.17 | $-7.83 | $-3.71 |
| Cash Flow | |||
| Operating CF | -$53.8M | -$10.8M | -$25.0M |
| CapEx | $171K | - | - |
Source: XBRL data in PALVELLA THERAPEUTICS, INC. (PVLA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PVLA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $529.6M |
| Q2 2026 | 27 | $595.9M |
| Q1 2026 | 26 | $377.7M |
| Q4 2025 | 22 | $243.6M |
| Q3 2025 | 21 | $119.0M |
| Q2 2025 | 15 | $31.0M |
| Q1 2025 | 10 | $13.7M |
| Q4 2024 | 5 | $520,000 |
- Invesco Ltd+279.1K (+829%)
- BlackRock+71.3K (+8%)
- Vanguard Capital Management LLC+26.9K (+5%)
- Bank of America Corp+14.2K (+26%)
- Northern Trust+9.9K (+10%)
- Goldman Sachs Group−49.7K (-25%)
- T. Rowe Price Group−46.9K (-7%)
- Morgan Stanley−36.4K (-20%)
- Millennium Management−33.1K (-63%)
- State Street Corp−28.3K (-4%)
- Blackstone Group+9.1K
- D.E. Shaw & Co+3.6K
- FMR LLC (Fidelity)−214.8K
- Raymond James Financial−23.7K
- Citadel Advisors LLC−3.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 152 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PVLA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 19, 2026 | - | Analysis | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 14, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| SC 13G | Aug 10, 2026 | - | - | |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| SC 13G | Aug 3, 2026 | - | - | |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PVLA SEC filings: frequently asked questions
Are PVLA insiders buying or selling?
In the last 90 days, PALVELLA THERAPEUTICS, INC. (PVLA) officers, directors and 10% owners reported no open-market purchases and 46 open-market sales worth $11.1 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PVLA stock?
As of September 30, 2026, the largest PALVELLA THERAPEUTICS, INC. (PVLA) holders among the 13F filers tracked by SignalX were BlackRock ($136.5 million), State Street Corp ($86.2 million), T. Rowe Price Group ($81.7 million), Vanguard Capital Management LLC ($74.6 million), Invesco Ltd ($43.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PVLA's revenue in fiscal year 2023?
For the fiscal year ended December 31, 2023 (FY2023), PALVELLA THERAPEUTICS, INC. (PVLA) reported revenue of $42.8 million and a net loss of $24.5 million. Diluted EPS was $2.17. The figures come from the XBRL data in the 10-K.
What did PVLA report in its latest 8-K?
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K on November 19, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). New QTORIN™ program announced as the third product candidate from Palvella’s platform.
What are the latest PVLA SEC filings?
PALVELLA THERAPEUTICS, INC. (PVLA) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 12, 2026.
What is PVLA's SEC CIK number?
PALVELLA THERAPEUTICS, INC. (PVLA)'s SEC Central Index Key (CIK) is 1583648. EDGAR lists every PVLA filing under that number.
Ask anything about PVLA
The research agent reads PVLA's filings, financials, insider trades and 13F holders, then answers with sources.